BCL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Based on genetic alterations in CTCL that may affect BCL2, we identified BCL2 as promising target in CTCL, and revealed that the BCL2 inhibitor venetoclax exhibits marked activity against CTCL viability [24], an effect synergistically potentiated by HDAC inhibitors, vorinostat and romidepsin (both agents have been previously approved by the U.S. FDA for CTCL) [10].